Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANNOAC
2022-501912-32-00Phase 4Authorised
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabigatran, apixaban, rivaroxaban and edoxaban in Atrial fibrillation (AFib), atrial flutter (AFL), deep vein thrombosis (DVT) and 1 more (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoints: Primary composite endpoint for DANNOAC-AF and Primary composite endpoint for DANNOAC-VTE. Planned start Nov 2022; status: authorised.
02
Drugs
dabigatranapixabanrivaroxabanedoxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2022-501912-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501912-32-00.